4.6 Article

Optimization of biosurfactant and bacteriocin-like inhibitory substance (BLIS) production by Lactococcus lactis CECT-4434 from agroindustrial waste

Journal

BIOCHEMICAL ENGINEERING JOURNAL
Volume 133, Issue -, Pages 168-178

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bej.2018.02.011

Keywords

Lactococcus lactis; Biosurfactant; Bacteriocin-like inhibitory substances; Low-cost substrates; Whey; Central composite design

Funding

  1. Sao Paulo Research Foundation (FAPESP) [2013/15065-0]
  2. Coordination of High-Level Personnel Training (CAPES) [88881.062223/2014-01]

Ask authors/readers for more resources

The use of low-cost substrates and wastes as fermentative media is a simple strategy for overcoming excessive production costs of bioactive molecules and to make the process more profitable. In this context, the aim of this work was to optimize the production of biosurfactant by Lactococcus lactis CECT-4434 from whey and vinasse from industrial sources. For this purpose, a 2(4) central composite design (CCD) was proposed to maximize biosurfactant production. Besides, the ability of Lc. lactis to synthesize bacteriocin-like inhibitory substance (BLIS) was also evaluated, therefore contributing to the profitability of the biotechnological process. Results showed that whey at 15% positively influenced biosurfactant production (on average 8.9 mg/L), reducing surface tension by about 18.1 mN/m. Molecular composition of the biosurfactant was determined by Fourier transform infrared spectroscopy and nuclear magnetic resonance which confirmed the presence of carbohydrates, lipids and proteins, defining this molecule as a glycolipopeptide. Regarding the BLIS synthesis, the highest concentration of sucrose (2.0%) and the lowest vinasse level (1.0%) reduced the production of BLIS identified by the decrease in antimicrobial activity (mean inhibition zone of 10.7 mm). Conversely, the lowest sucrose concentration and highest vinasse level exerted the strongest inhibition, with a mean inhibition zone of 12.2 mm against Staphylococcus aureus CECT-239. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available